دورية أكاديمية
Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics
| العنوان: | Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics |
|---|---|
| المؤلفون: | Gao, Julia L, Streed, Carl G, Thompson, Julie, Dommasch, Erica D, Peebles, Jon Klinton |
| المصدر: | GW Authored Works |
| بيانات النشر: | Health Sciences Research Commons |
| سنة النشر: | 2023 |
| المجموعة: | George Washington University: Health Sciences Research Commons (HSRC) |
| مصطلحات موضوعية: | FTM, LGBT, LLLLT, LLLT, MTF, PRP, alopecia, androgenetic alopecia, bisexual, dermatology, dutasteride, finasteride, gay, gender diversity, gender identity disorder, gender minority, gender queer, gender-diverse, general dermatology, hair loss, hair restoration procedure, hairline advancement, hairline transplantation, health disparities, lesbian, low-level laser light therapy, medical dermatology, minoxidil, platelet-rich plasma, sexual minority |
| الوصف: | Androgenetic alopecia (AGA) management is a significant clinical and therapeutic challenge for transgender and gender-diverse (TGD) patients. Although gender-affirming hormone therapies affect hair growth, there is little research about AGA in TGD populations. After reviewing the literature on approved treatments, off-label medication usages, and procedures for treating AGA, we present treatment options for AGA in TGD patients. The first-line treatments for any TGD patient include topical minoxidil 5% applied to the scalp once or twice daily, finasteride 1 mg oral daily, and/or low-level laser light therapy. Spironolactone 200 mg daily is also first-line for transfeminine patients. Second-line options include daily oral minoxidil dosed at 1.25 or 2.5 mg for transfeminine and transmasculine patients, respectively. Topical finasteride 0.25% monotherapy or in combination with minoxidil 2% solution are second-line options for transmasculine and transfeminine patients, respectively. Other second-line treatments for any TGD patient include oral dutasteride 0.5 mg daily, platelet-rich plasma, or hair restoration procedures. After 6-12 months of treatment, AGA severity and treatment progress should be assessed via scales not based on sex; eg, the Basic and Specific Classification or the Bouhanna scales. Dermatologists should coordinate care with the patient's primary gender-affirming clinician(s) so that shared knowledge of all medications exists across the care team. |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://hsrc.himmelfarb.gwu.edu/gwhpubs/3710Test; https://doi.org/10.1016/j.jaad.2021.08.067Test |
| DOI: | 10.1016/j.jaad.2021.08.067 |
| الإتاحة: | https://doi.org/10.1016/j.jaad.2021.08.067Test https://hsrc.himmelfarb.gwu.edu/gwhpubs/3710Test |
| رقم الانضمام: | edsbas.C7C0C8E1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.jaad.2021.08.067 |
|---|